# CRAF (RAF1)

Source: https://onco.cc/targets/raf1/  
OnCo record `raf1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CRAF is BRAF's sibling in the growth-signal relay; sorafenib and regorafenib were designed against it, and it is the route by which RAS-mutant tumours escape BRAF-only drugs.

## Summary

RAF1 (CRAF) is one of three RAF kinases that pass the signal from RAS to MEK. Sorafenib was originally developed as a CRAF inhibitor before its VEGF receptor activity explained its clinical effect, and regorafenib shares that profile. CRAF matters clinically because RAS-mutant and BRAF-inhibitor-treated tumours signal through CRAF dimers, the basis for pan-RAF inhibitors now in trials.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Symbol: RAF1
- Class: kinase
- Biology: Activated by RAS-GTP at the membrane and by dimerisation; it also has kinase-independent roles in blocking apoptosis.
- Where found: All tissues; Drives MAPK signalling in RAS-mutant tumours and in resistance to BRAF inhibitors

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/C-Raf
- UniProt P04049: RAF1: https://www.uniprot.org/uniprotkb/P04049/entry
- HGNC:9829 RAF1: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9829
- ChEMBL target CHEMBL1906: https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1906

## Connected records

- targets: [BRAF](https://onco.cc/targets/braf/), [MEK1/2](https://onco.cc/targets/mek/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Regorafenib](https://onco.cc/drugs/regorafenib/), [Sorafenib](https://onco.cc/drugs/sorafenib/)

---
JSON: https://onco.cc/api/v1/entities/raf1.json